Next-Gen Obesity Drug Outperforms GLP-1s in Mice
A preclinical next-generation obesity drug is stacking five distinct mechanisms of action, delivering superlative effectiveness in mice. This development could position the drug as a potential successor to widely used GLP-1 medications like semaglutide and tirzepatide.
NIH Funding Crisis Deepens for Researchers
The odds of securing an NIH grant have plummeted to historically low levels. According to STAT’s Anil Oza, only 13% of applications were funded last year, leaving even top-scoring proposals with uncertain prospects. Researchers now face a hypercompetitive and opaque funding environment, forcing many to reconsider their scientific pursuits.
Pharma Earnings Roundup: Merck, Bristol Myers Squibb, and Eli Lilly
Major pharmaceutical companies continue to report earnings:
- Merck – Notable financial updates.
- Bristol Myers Squibb – Earnings and pipeline developments.
- Eli Lilly – Financial performance and obesity drug market impact.
Notable Biotech Updates
Alnylam – Significant biotech earnings reported.
UniQure – The company announced plans to submit a marketing application for its Huntington’s disease gene therapy to U.K. regulators in the third quarter of this year.
Industry Milestones and Losses
Craig Venter, genomic pioneer and entrepreneur, passes away.
Novartis Reshores Manufacturing Operations
Novartis is increasing its domestic manufacturing footprint as part of broader reshoring efforts within the pharmaceutical industry.
Related articles
STAT+ Roundup: New Hires and Promotions in Biotech and Pharma
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others....
GLP-1 Drugs Linked to Better Breast Cancer Outcomes in Obesity and Diabetes Patients
A recent study shows that GLP-1 drugs may help improve survival rates in people with breast cancer, obesity, and diabetes. Image Credit: Tatsiana Volk...
UK Political Shake-Up Could Reshape Global Drug Pricing Policies
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Congrats on...
U.S. Pressures Germany on Drug Prices Amid FDA Restructuring Concerns
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about we...
FDA Rejects Melanoma Drug RP1 Amid Leadership Controversy Under Makary
The FDA’s recent decision to withhold approval of a new skin cancer treatment fell like a hammer on doctors who treat melanoma and patients who saw th...
Why Changing Pill Colors and Shapes at 73 Are More Than Just an Annoyance
At the ripe old age of 73, I take six drugs — four prescription and two over-the-counter pills — every day. I keep careful track of them. But recently...
Craig Venter’s Legacy in Genomics: Maverick Who Challenged Scientific Norms
Two weeks ago, one of the most important scientists of the 20th century died. Craig Venter was a legend in genomics — a self-styled maverick who made...
Dr. Makary's Exit and the Future of Cassidy's Senate Seat: Key Health Policy Shifts
This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he...